HealthyPhase 1NCT03405441
A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants
A Phase 1 study testing JNJ-55375515 Dose Level 1, JNJ-55375515 Dose Level 2 and JNJ-55375515 Dose Level 3 in people with Healthy, run by Janssen Research & Development, LLC at 1 site in Netherlands.
Trial summary
The purpose of this study is to assess safety and tolerability of day-time and night-time dosing of JNJ-55375515 in healthy male participants. Read more about this study
- Who is it for?
- Ages 18 to 54 years, men onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- JNJ-55375515 Dose Level 1, JNJ-55375515 Dose Level 2 and JNJ-55375515 Dose Level 3
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 42 participants
- Where
- 1 siteNetherlands
- Study dates
- 2 Jan 2018to 4 Sep 2018
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 54 years
- Men only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Body Mass Index (BMI) between 18 and 30 kilogram / square meter (kg/m^2) inclusive (BMI=weight/height^2)
- Participant must be healthy based on clinical laboratory tests performed at screening. If the results of the serum chemistry panel, hematology, coagulation or urinalysis are outside the normal reference ranges, retesting of an abnormal lab value (s) that may lead to exclusion will be allowed once during the screening phase. It is expected that laboratory values will generally be within the normal range for the laboratory, though minor deviations, which are not considered to be of clinical significance to the investigator, are acceptable
- Participant must be healthy based on physical and neurological examination, medical history, vital signs, and 12-lead Electrocardiography (ECG) [including QTcF less than or equal to (<=) 450 millisecond (msec)] performed at screening, admission to the clinical unit and pre dose on Day 1 of Period 1. Abnormalities, which are not considered to be of clinical significance by the investigator, are acceptable. The presence of Left Bundle Branch Block (LBBB), AV Block (second degree or higher), or a permanent pacemaker or implantable cardioverter defibrillator [ICD] will lead to exclusion
- Non-smoker (not smoked for 3 months prior to screening)
- During the study and for a minimum of 1 spermatogenesis cycle (defined as approximately 90 days) after receiving the last dose of study drug, in addition to the highly effective method of contraception, a man who is sexually active with a woman of childbearing potential must agree to use a barrier method of contraception (for example, condom with spermicidal foam/gel/film/cream/suppository); who is sexually active with a woman who is pregnant must use a condom; must agree not to donate sperm
Who cannot join
- History of or current significant medical illness including (but not limited to psychotic, bipolar, major depressive, or anxiety disorder)
- Cardiac arrhythmias or other cardiac disease, hematological disease, lipid abnormalities, respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, Parkinson's disease, infection, or any other illness that the Investigator considers should exclude the participant
- Serology positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies or human immunodeficiency virus (HIV) antibodies
- Participant has a history of or current vestibular disease including (but not limited to) Meniere's disease, benign paroxysmal positional vertigo (BPPV), vestibular neuronitis, vestibular schwannoma or vestibular migraine
- Only for part 2: Has a current diagnosis or history of narcolepsy, central sleep apnea, sleep related hypoventilation, circadian rhythm sleep-wake disorders, substance/medication induced sleep disorder or parasomnias (non-rapid eye movement sleep arousal disorders, nightmare disorder, rapid eye movement sleep behavior disorder); obstructive sleep apnea/hypopnea (apnea/hypopnea index greater than (>)10) or restless legs syndrome (periodic leg movements with arousal index >15); night-shift worker or significantly shifted diurnal activity pattern (it is expected that eligible participant normally wake up between 6:00 am - 8:00 am and go to bed between 10:00 pm - 12:00 am); usual bedtime outside of 10:00 pm and 12:00 am and taking, on average, less than 6 hours or more than 9 hours of bed rest
Trial locations and contacts
1 site in 1 country.
Netherlands1 site
PRA Health Sciences Onderzoekscentrum Groningen, locatie Martini
Groningen, 9728 NZ
About this study
Official title: A 2-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Subjects
The purpose of this study is to assess safety and tolerability of day-time and night-time dosing of JNJ-55375515 in healthy male participants.
- Conditions
- Healthy
- Being tested
- JNJ-55375515 Dose Level 1, JNJ-55375515 Dose Level 2, JNJ-55375515 Dose Level 3, JNJ-55375515 Dose Level 4, JNJ-55375515 Dose Level 5
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
JNJ-55375515 Dose Level 1Drug
Participants will receive JNJ-55375515 orally at a Dose level 1 in Part 1 of study.
JNJ-55375515 Dose Level 2Drug
Participants will receive JNJ-55375515 orally at a Dose level 2 in Part 1 of study.
JNJ-55375515 Dose Level 3Drug
Participants will receive JNJ-55375515 orally at a Dose level 3 in Part 1 of study.
JNJ-55375515 Dose Level 4Drug
Participants will receive JNJ-55375515 orally at a Dose level 4 in Part 1 of study.
JNJ-55375515 Dose Level 5Drug
Participants will receive JNJ-55375515 orally at a Dose level 5 in Part 1 of study.
JNJ-55375515 Dose Level 6Drug
Participants will receive JNJ-55375515 orally at a Dose level 6 in Part 1 of study.
PlaceboDrug
All participants will receive matching placebo orally in Part 1 and Part 2 of the study.
JNJ-55375515Drug
Participants will receive JNJ-55375515 as per the assigned treatment in Part 2.
| Study group | Role | What they receive |
|---|---|---|
| Part 1 (Panel 1): JNJ-55375515 and placebo | Experimental | Participants will receive dose level (DL) 1 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 3 (period 2) and a maximum of DL 5 (period 3) based on the safety and tolerability profile and pharmacodynamic (PD) profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations. Receives: Drug: JNJ-55375515 Dose Level 1; Drug: JNJ-55375515 Dose Level 3; Drug: JNJ-55375515 Dose Level 5; Drug: Placebo |
| Part 1 (Panel 2): JNJ-55375515 and placebo | Experimental | Participants will receive DL 2 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 4 (period 2) and a maximum of DL 6 (period 3) based on the safety and tolerability profile and PD profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations. Receives: Drug: JNJ-55375515 Dose Level 2; Drug: JNJ-55375515 Dose Level 4; Drug: JNJ-55375515 Dose Level 6; Drug: Placebo |
| Part 2: JNJ-55375515 and placebo | Experimental | Participants will randomly be assigned to one of four treatment sequences 1, 2, 3 or 4. In the first 3 sequences, participants will receive 2 doses of JNJ-55375515 and placebo. Participants assigned to sequence 4 will receive placebo only in all periods. 3 dose levels will be tested in Part 2 based on Part 1 and will not exceed those evaluated in Part 1. A wash-out period of at least 10 days will be maintained between study drug administrations in period 1, 2, 3 and 4. In period 4 (open-label pharmacokinetic (PK) assessment period) participants will be randomly assigned to one of two dose levels tested in periods 1 to 3. Receives: Drug: Placebo; Drug: JNJ-55375515 |
What is being measured
The primary outcome is the main question the study is designed to answer.
Part 1 (Day-Time Dosing): Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Measured: Up to Week 8
Part 2 (Night-Time Dosing): Number of Participants with AEs as a Measure of Safety and Tolerability
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Measured: Up to Week 9
Secondary outcomes (25)
Slow Wave Activity Recorded by the Electroencephalogram (EEG)
The Effect of JNJ-55375515 on slow wave activity recorded by the electroencephalogram (EEG) will be evaluated. EEG recordings are made using gold electrodes, fixed at Midline Frontal Electrode (Fz), Midline Central Electrode (Cz), Midline Parietal Electrode (Pz) and Midline Occipital Electrode (Oz), with the same common ground electrode as for the eye movement registration (international 10/20 system). Per session eight consecutive blocks of eight seconds are recorded. For each lead, fast Fourier transform analysis will be performed to obtain the sum of amplitudes in the very low (0.5-2 Hertz [Hz]), delta- (2-4 Hz), theta (4-7.5 Hz), alpha- (7.5-13.5 Hz), beta- (13.5-35 Hz), and gamma-(35-48.9 Hz) frequency ranges. The total test will last approximately 2 minutes.
Measured: Pre-dose, 1 hour (h), 2h, and 4h post dose on Day 1
Part 1: PD of JNJ-55375515 as Assessed by Heart Rate Variability (HRV)
Heart rate variability (HRV) is the physiological phenomenon of variation in the time interval between heartbeats. It is measured by the variation in the beat-to-beat interval. HRV will be derived from Holter recordings. Holter recordings will start pre dose on Day 1 of each period in Part 1 and continue for 24 hours. Measurements will be made at rest (during 5 minutes) and HRV parameters will be derived from these 5-minute recordings and from the 24-hour recordings.
Measured: Pre-dose (Day 1) up to 24 hours post dose
Part 1: Saccadic Reaction Time (RT) as Measured by Saccadic Eye Movements
Saccadic eye movements will be recorded to measure saccadic reaction time (RT). The recording and analysis of saccadic eye movements is performed using a computer-based system for sampling and analysis of eye movements. In a typical test system, electrodes are applied on the forehead and beside the lateral canthi of both eyes of the participant for registration of the electro-oculographic signals. Head movements are restrained using a fixed head support. The target consists of a moving dot that is displayed on a computer screen. Fifteen saccades are recorded with inter-stimulus intervals varying randomly between 3 and 6 seconds. Average values of latency (reaction time) of all correct saccades will be assessed.
Measured: Pre-dose, 1 h, 2h, and 4h post dose on Day 1
Part 1: Saccadic Peak Velocity (SPV) as Measured by Saccadic Eye Movements
Saccadic eye movements will be recorded to measure saccadic peak velocity (SPV). The recording and analysis of saccadic eye movements is performed using a computer-based system for sampling and analysis of eye movements. In a typical test system, electrodes are applied on the forehead and beside the lateral canthi of both eyes of the participant for registration of the electro-oculographic signals. Head movements are restrained using a fixed head support. The target consists of a moving dot that is displayed on a computer screen. Fifteen saccades are recorded with inter-stimulus intervals varying randomly between 3 and 6 seconds. Average values of saccadic peak velocity of all correct saccades will be assessed.
Measured: Pre-dose, 1h, 2h, and 4h post dose on Day 1
Part 1: Change from Baseline in Body Sway
The body sway meter allows measurement of body movements in a single plane, providing a measure of postural stability. Body sway may be measured with a pot string meter (Celesco) based on the Wright ataxiameter or platform. Participants will be instructed to wear a pair of comfortable, low-heeled shoes on each session. The total period of body-sway measurement will be 2 minutes.
Measured: Baseline, 1h, 2h, and 4h post dose on Day 1
Part 1 and 2: PD as Assessed by Karolinska Sleepiness Scale (KSS) Score
The KSS is a patient reported assessment of drowsiness level at the time of scale administration. This scale is focused mainly on the propensity to fall asleep and has a high validity in assessing sleepiness. It consists of a 9-point Likert scale with response options from: 1=very alert, 3=alert, 5=neither alert nor sleepy, 7=sleepy (but not fighting sleep), 9=very sleepy (fighting sleep).
Measured: Part 1: Pre-dose, 1h, 3h, and 8h post dose on Day 1; Part 2: Pre-dose (Day 1) and 8h post dose (Day 2)
Part 1: Change from Baseline in Bond and Lader Visual Analogue Scale (B&L VAS) Score
The Bond and Lader Visual Analogue Scale consists of sixteen 100 millimeter (mm) visual analog scales anchored by antonyms (example, Alert-Drowsy, Lethargic-Energetic, etc). Scores will be combined to form three mood factors: alertness, calmness, and contentedness.
Measured: Baseline, 1h, 2h, and 4h post dose on Day 1
Part 1 and 2: Change from Baseline in Cortisol Levels
To establish diurnal levels of cortisol levels, repeated serum samples will be obtained throughout the Day 1 of each period. The diurnal cortisol levels will be explored to further clarify the effect of the compound on the hypothalamic-pituitary-adrenal-axis.
Measured: Part 1: Baseline, 0.5h, 1h, 2h, 3h, 4h, 5h 45minutes (m), 6h, 6h 05m, 6h 25m, 6h 30m, 6h 50m, 6h 55m, 7h 15m, 7h 35m, 8h, 12h and 24h post dose on Day 1; Part 2: Baseline, 0.5h, 1h, 2h (Day 1 or 2), 3h, 4h, 6h, 8h, 12h and 24h post dose on Day 2
Part 1: PD as Assessed by Probabilistic Instrumental Learning Task (PILT)
In this motivational processing task, participants with depressive symptoms may show a lower response bias towards a reward compared to healthy participants. The PILT allows the objective assessment of participants propensity to modulate behavior as a function of reward.
Measured: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: International Shopping List Test
The International Shopping List Test is a measure of Verbal Memory-Learning. The test measures total number of correct responses remembering the 16-word list on three consecutive learning trials. Higher score indicates better performance.
Measured: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: Groton Maze Learning Task
Groton Maze Learning Task is a measure of Executive Function and Spatial Learning. The test measures total number of errors made while locating and learning 28 step pathway hidden beneath a 10*10 grid on 5 consecutive trials during a single session. Lower score indicates better performance.
Measured: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: Social Emotional Cognition Task
To evaluate social and emotional cognition, a series of tests will be used to quantify both the ability to empathize and understand the emotions of others, and the ability to interpret their thoughts and intentions. A classical test involves the presentation of facial expressions and is asked to choose which word best describes what the person in the image is thinking or trying.
Measured: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: Detection Task
Detection task is a measure of Psychomotor Function. The test measures speed of performance; mean of the log10 transformed reaction times for correct responses. Lower score indicates better performance.
Measured: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: Identification Task
Identification task is a measure of Attention. The test measures speed of performance; mean of the log10 transformed reaction times for correct responses. Lower score indicates better performance.
Measured: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: one Back Task
One back task is a measure of Working Memory. The test measures speed of performance; mean of the log10 transformed reaction times for correct responses. Lower score indicates better performance.
Measured: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: International Shopping List Test - Delayed Recall
International shopping list test - Delayed Recall is a measure of Delayed Verbal Memory. The test measures total number of correct responses recalling the 16 words learned previously after a delay. Higher score indicates better performance.
Measured: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: Groton Maze Learning - Delayed Recall
Groton Maze Learning - Delayed recall is a measure of Delayed Spatial Memory. The test measures number of errors made while locating 28 step pathway hidden beneath a 10*10 grid after a delay. Lower score indicates better performance.
Measured: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: Evoked Stress Response as Assessed by Induced Stress
The induced stress test consists of a highly demanding computer task that is performed for 20 minutes.
Measured: 6h 30m to 6h 50m post dose on Day 1
Part 2: Latency to Persistent Sleep (LPS) by 8-hour Overnight Polysomnography
LPS is the time in minutes from 'lights out' that marks the starting of total recording time to the first epoch scored as sleep.
Measured: 0 hour (Day 1) up to 8 Hour (Day 2)
Part 2: Total Time Spent in Deep Sleep (Duration of Slow Wave Sleep) - Stage 3 Sleep by 8-Hour Overnight Polysomnography
Polysomnographic recordings will be used to determine the total time spent in deep sleep (duration of slow wave sleep) -stage 3 sleep by 8-hour overnight.
Measured: 0 hour (Day 1) up to 8 Hour (Day 2)
Part 2: Time in bed by 8-hour Overnight Polysomnography
Polysomnographic recordings will be used to determine the time in bed by 8-hour overnight.
Measured: 0 hour (Day 1) up to 8 Hour (Day 2)
Part 2: Cognitive Test Battery: Continuous Paired Associate Learning Task (CPAL)
The Continuous Paired Associate Learning (CPAL) test will be used to assess whether JNJ-55375515 will improve performance of complex cognitive tasks. CPAL assess Visual episodic memory (associate learning) cognitive domain. In this task, participants must learn a series of associations between a set of difficult to verbalize patterns (amoeba) and locations. In healthy adults, 14 pattern/location associations must be learned. In the presentation phase of the task the pattern appears at the location and the participant is required to acknowledge that they have seen the pattern by touching the location at which it appears. Patterns are presented in random order. In the learning phase of the task, participants must place each of the 14 patterns in their correct locations. They must do this in 10 rounds. Number of errors made in correctly placing each of the four patterns in their location four times. (Lower score = better performance).
Measured: -7 hour (Day 1), 17 hour (Day 2)
Part 1 and 2: Maximum Observed Plasma Concentration (Cmax)
Cmax is the maximum observed plasma concentration.
Measured: Part 1: Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, and 96h post dose; Part 2: Pre dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 46h, 70h, and 94h post dose
Part 1 and 2: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Tmax is defined as actual sampling time to reach maximum observed analyte concentration.
Measured: Part 1: Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, and 96h post dose; Part 2: Pre dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 46h, 70h, and 94h post dose
Part 1 and 2: Area Under the Plasma Concentration-Time Curve from Time 0 to Time of the Last Quantifiable Concentrations (AUC[0-last])
AUC(0-last) is area under the plasma concentration-time curve from time 0 to time of the last quantifiable concentrations.
Measured: Part 1: Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, and 96h post dose; Part 2: Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 46h, 70h, and 94h post dose
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Jan 2018
- Study start2 Jan 2018
- Primary completion4 Sep 2018
- Study completion4 Sep 2018
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- More trials run by Janssen Research & Development, LLCThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 42 participants (actual)
Sponsor and investigators
- Lead sponsor
- Janssen Research & Development, LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Janssen Research & Development, LLC Clinical Trial, Study director, Janssen Research & Development, LLC
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03405441
- Sponsor's protocol ID
- CR108409
- Other IDs
- 55375515EDI1002, 2017-002457-11, 2017
- Status last verified
- Apr 2025
- First submitted
- 8 Jan 2018
- Last updated
- 27 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A 2-Part, Randomized, Placebo-controlled, Double-blind, Single Ascending Dose Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Subjects
- ClinicalTrials.gov ID
- NCT03405441
- Acronym / sponsor ID
- CR108409
- Conditions
- Healthy
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 42 participants (actual)
- Lead sponsor
- Janssen Research & Development, LLCIndustry (pharma, biotech, devices)
- Study start
- 2 Jan 2018 (actual)
- Primary completion
- 4 Sep 2018 (actual)
- Study completion
- 4 Sep 2018 (actual)
- First posted
- 23 Jan 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess safety and tolerability of day-time and night-time dosing of JNJ-55375515 in healthy male participants.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Part 1 (Panel 1): JNJ-55375515 and placebo | Experimental | Drug: JNJ-55375515 Dose Level 1, Drug: JNJ-55375515 Dose Level 3, Drug: JNJ-55375515 Dose Level 5, Drug: PlaceboParticipants will receive dose level (DL) 1 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 3 (period 2) and a maximum of DL 5 (period 3) based on the safety and tolerability profile and pharmacodynamic (PD) profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations. |
| Part 1 (Panel 2): JNJ-55375515 and placebo | Experimental | Drug: JNJ-55375515 Dose Level 2, Drug: JNJ-55375515 Dose Level 4, Drug: JNJ-55375515 Dose Level 6, Drug: PlaceboParticipants will receive DL 2 of JNJ-55375515 (starting dose) or placebo on Day 1 of period 1 based on their randomization sequence 1, 2 or 3. Dose of the study medication will be escalated to DL 4 (period 2) and a maximum of DL 6 (period 3) based on the safety and tolerability profile and PD profile assessed at the preceding dose level. A wash-out period of at least 10 days will be maintained between study drug administrations. |
| Part 2: JNJ-55375515 and placebo | Experimental | Drug: Placebo, Drug: JNJ-55375515Participants will randomly be assigned to one of four treatment sequences 1, 2, 3 or 4. In the first 3 sequences, participants will receive 2 doses of JNJ-55375515 and placebo. Participants assigned to sequence 4 will receive placebo only in all periods. 3 dose levels will be tested in Part 2 based on Part 1 and will not exceed those evaluated in Part 1. A wash-out period of at least 10 days will be maintained between study drug administrations in period 1, 2, 3 and 4. In period 4 (open-label pharmacokinetic (PK) assessment period) participants will be randomly assigned to one of two dose levels tested in periods 1 to 3. |
Who may qualify
- Ages
- 18 to 54 years
- Sex
- Male only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (5 listed)
- Body Mass Index (BMI) between 18 and 30 kilogram / square meter (kg/m^2) inclusive (BMI=weight/height^2)
- Participant must be healthy based on clinical laboratory tests performed at screening. If the results of the serum chemistry panel, hematology, coagulation or urinalysis are outside the normal reference ranges, retesting of an abnormal lab value (s) that may lead to exclusion will be allowed once during the screening phase. It is expected that laboratory values will generally be within the normal range for the laboratory, though minor deviations, which are not considered to be of clinical significance to the investigator, are acceptable
- Participant must be healthy based on physical and neurological examination, medical history, vital signs, and 12-lead Electrocardiography (ECG) [including QTcF less than or equal to (<=) 450 millisecond (msec)] performed at screening, admission to the clinical unit and pre dose on Day 1 of Period 1. Abnormalities, which are not considered to be of clinical significance by the investigator, are acceptable. The presence of Left Bundle Branch Block (LBBB), AV Block (second degree or higher), or a permanent pacemaker or implantable cardioverter defibrillator [ICD] will lead to exclusion
- Non-smoker (not smoked for 3 months prior to screening)
- During the study and for a minimum of 1 spermatogenesis cycle (defined as approximately 90 days) after receiving the last dose of study drug, in addition to the highly effective method of contraception, a man who is sexually active with a woman of childbearing potential must agree to use a barrier method of contraception (for example, condom with spermicidal foam/gel/film/cream/suppository); who is sexually active with a woman who is pregnant must use a condom; must agree not to donate sperm
Key exclusion criteria (5 listed)
- History of or current significant medical illness including (but not limited to psychotic, bipolar, major depressive, or anxiety disorder)
- Cardiac arrhythmias or other cardiac disease, hematological disease, lipid abnormalities, respiratory disease, diabetes mellitus, renal or hepatic insufficiency, thyroid disease, Parkinson's disease, infection, or any other illness that the Investigator considers should exclude the participant
- Serology positive for hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies or human immunodeficiency virus (HIV) antibodies
- Participant has a history of or current vestibular disease including (but not limited to) Meniere's disease, benign paroxysmal positional vertigo (BPPV), vestibular neuronitis, vestibular schwannoma or vestibular migraine
- Only for part 2: Has a current diagnosis or history of narcolepsy, central sleep apnea, sleep related hypoventilation, circadian rhythm sleep-wake disorders, substance/medication induced sleep disorder or parasomnias (non-rapid eye movement sleep arousal disorders, nightmare disorder, rapid eye movement sleep behavior disorder); obstructive sleep apnea/hypopnea (apnea/hypopnea index greater than (>)10) or restless legs syndrome (periodic leg movements with arousal index >15); night-shift worker or significantly shifted diurnal activity pattern (it is expected that eligible participant normally wake up between 6:00 am - 8:00 am and go to bed between 10:00 pm - 12:00 am); usual bedtime outside of 10:00 pm and 12:00 am and taking, on average, less than 6 hours or more than 9 hours of bed rest
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| JNJ-55375515 Dose Level 1Participants will receive JNJ-55375515 orally at a Dose level 1 in Part 1 of study. | Drug | Part 1 (Panel 1): JNJ-55375515 and placebo |
| JNJ-55375515 Dose Level 2Participants will receive JNJ-55375515 orally at a Dose level 2 in Part 1 of study. | Drug | Part 1 (Panel 2): JNJ-55375515 and placebo |
| JNJ-55375515 Dose Level 3Participants will receive JNJ-55375515 orally at a Dose level 3 in Part 1 of study. | Drug | Part 1 (Panel 1): JNJ-55375515 and placebo |
| JNJ-55375515 Dose Level 4Participants will receive JNJ-55375515 orally at a Dose level 4 in Part 1 of study. | Drug | Part 1 (Panel 2): JNJ-55375515 and placebo |
| JNJ-55375515 Dose Level 5Participants will receive JNJ-55375515 orally at a Dose level 5 in Part 1 of study. | Drug | Part 1 (Panel 1): JNJ-55375515 and placebo |
| JNJ-55375515 Dose Level 6Participants will receive JNJ-55375515 orally at a Dose level 6 in Part 1 of study. | Drug | Part 1 (Panel 2): JNJ-55375515 and placebo |
| PlaceboAll participants will receive matching placebo orally in Part 1 and Part 2 of the study. | Drug | Part 1 (Panel 1): JNJ-55375515 and placebo, Part 1 (Panel 2): JNJ-55375515 and placebo, Part 2: JNJ-55375515 and placebo |
| JNJ-55375515Participants will receive JNJ-55375515 as per the assigned treatment in Part 2. | Drug | Part 2: JNJ-55375515 and placebo |
Primary outcome
Part 1 (Day-Time Dosing): Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability
Time frame: Up to Week 8
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
Part 2 (Night-Time Dosing): Number of Participants with AEs as a Measure of Safety and Tolerability
Time frame: Up to Week 9
An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship.
25 secondary outcomes
Slow Wave Activity Recorded by the Electroencephalogram (EEG)
Time frame: Pre-dose, 1 hour (h), 2h, and 4h post dose on Day 1
Part 1: PD of JNJ-55375515 as Assessed by Heart Rate Variability (HRV)
Time frame: Pre-dose (Day 1) up to 24 hours post dose
Part 1: Saccadic Reaction Time (RT) as Measured by Saccadic Eye Movements
Time frame: Pre-dose, 1 h, 2h, and 4h post dose on Day 1
Part 1: Saccadic Peak Velocity (SPV) as Measured by Saccadic Eye Movements
Time frame: Pre-dose, 1h, 2h, and 4h post dose on Day 1
Part 1: Change from Baseline in Body Sway
Time frame: Baseline, 1h, 2h, and 4h post dose on Day 1
Part 1 and 2: PD as Assessed by Karolinska Sleepiness Scale (KSS) Score
Time frame: Part 1: Pre-dose, 1h, 3h, and 8h post dose on Day 1; Part 2: Pre-dose (Day 1) and 8h post dose (Day 2)
Part 1: Change from Baseline in Bond and Lader Visual Analogue Scale (B&L VAS) Score
Time frame: Baseline, 1h, 2h, and 4h post dose on Day 1
Part 1 and 2: Change from Baseline in Cortisol Levels
Time frame: Part 1: Baseline, 0.5h, 1h, 2h, 3h, 4h, 5h 45minutes (m), 6h, 6h 05m, 6h 25m, 6h 30m, 6h 50m, 6h 55m, 7h 15m, 7h 35m, 8h, 12h and 24h post dose on Day 1; Part 2: Baseline, 0.5h, 1h, 2h (Day 1 or 2), 3h, 4h, 6h, 8h, 12h and 24h post dose on Day 2
Part 1: PD as Assessed by Probabilistic Instrumental Learning Task (PILT)
Time frame: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: International Shopping List Test
Time frame: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: Groton Maze Learning Task
Time frame: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: Social Emotional Cognition Task
Time frame: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: Detection Task
Time frame: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: Identification Task
Time frame: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: one Back Task
Time frame: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: International Shopping List Test - Delayed Recall
Time frame: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: PD as Assessed by Cognitive Test Battery: Groton Maze Learning - Delayed Recall
Time frame: Pre-dose, 3h, and 8h post dose on Day 1
Part 1: Evoked Stress Response as Assessed by Induced Stress
Time frame: 6h 30m to 6h 50m post dose on Day 1
Part 2: Latency to Persistent Sleep (LPS) by 8-hour Overnight Polysomnography
Time frame: 0 hour (Day 1) up to 8 Hour (Day 2)
Part 2: Total Time Spent in Deep Sleep (Duration of Slow Wave Sleep) - Stage 3 Sleep by 8-Hour Overnight Polysomnography
Time frame: 0 hour (Day 1) up to 8 Hour (Day 2)
Part 2: Time in bed by 8-hour Overnight Polysomnography
Time frame: 0 hour (Day 1) up to 8 Hour (Day 2)
Part 2: Cognitive Test Battery: Continuous Paired Associate Learning Task (CPAL)
Time frame: -7 hour (Day 1), 17 hour (Day 2)
Part 1 and 2: Maximum Observed Plasma Concentration (Cmax)
Time frame: Part 1: Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, and 96h post dose; Part 2: Pre dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 46h, 70h, and 94h post dose
Part 1 and 2: Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Part 1: Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, and 96h post dose; Part 2: Pre dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 46h, 70h, and 94h post dose
Part 1 and 2: Area Under the Plasma Concentration-Time Curve from Time 0 to Time of the Last Quantifiable Concentrations (AUC[0-last])
Time frame: Part 1: Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, and 96h post dose; Part 2: Pre-dose, 0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 46h, 70h, and 94h post dose
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2025.
Related trials for Healthy
Recruiting
THE EFFECTS OF GAME-BASED EXERCISE PROGRAMS
Physical Activity, Body Image
Not yet recruitingPhase 1
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants
Atopic Dermatitis
Recruiting
Colon-delivered Riboflavin and Gut Microbiota Composition
Microbiome Dysbiosis, Gut Health
Not yet recruiting
Neuroergonomic Analysis of a Brain-Computer Interface Device (BCI)
Healthy Volunteers - Male and Female
RecruitingPhase 1
First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
Healthy Volunteer, Atopic Dermatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Janssen Research & Development, LLC Clinical Trial study director
Janssen Research & Development, LLC
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing JNJ-55375515 Dose Level 1, JNJ-55375515 Dose Level 2 and JNJ-55375515 Dose Level 3 in people with Healthy, run by Janssen Research & Development, LLC at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Part 1 (Day-Time Dosing): Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability (time frame: Up to Week 8). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2025.